Clinical trials: Resolution
Alzheimer Disease, Dementia
A Mobile Informatics Solution to Aid in Memory
The researchers propose to develop an informatics system to assist people with memory impairment. Persons with Memory Concern (PWMC) recognize the faces they see daily, such as a spouse or caregiver, but they may confuse visiting…
- Trial name
- NCT04700540
- Testing
- Smartwatch Reminder (SR) system
- Where
- United States
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Refractive Error, Dry Eye
Determination of Cell Population in Solution-Induced Corneal Staining (SICS) and Symptomatic Versus Asymptomatic Lens Wearers
The purpose of the study is to investigate the corneal epithelial cell response associated with lens wear that results in solution-induced corneal staining (Phase1) and to determine the cell appearance in symptomatic and…
- Trial name
- ABBOTSFORD (NCT01629706)
- Testing
- Balafilcon A contact lens, Habitual contact lenses, Renu multi-purpose solution
- Volunteers
- 92 people
- Sponsor
- CIBA VISION
Neuroendocrine Tumors, Carcinoid Tumors
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging, and measurement of response to treatment in patients with somatostatin receptor positive tumors.
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumors, Neuroblastoma, Medulloblastoma
- Trial name
- GA-68 (NCT01619865)
- Testing
- 68Ga-DOTATOC PET/CT
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- Sue O'Dorisio
Constipation
Safety and Tolerability of Oral Polyethylene Glycol (PEG 3350) Solution in Participants With Constipation (MK-8114-003)
The purpose of this study is to compare the safety and tolerability of oral ingestion of PEG 3350 solution concentrate to oral ingestion of a placebo solution concentrate, in participants with constipation.
- Trial name
- NCT01885104
- Testing
- Polyethylene Glycol (PEG 3350), Bisacodyl laxative tablets (rescue medication)
- Volunteers
- 65 people
- Sponsor
- Bayer
Blood Volume, Blood Coagulation
Volume Kinetics for Starch Solution and Acetated Ringers
Volume kinetics is a method mostly used, so far, to study the distribution and elimination of crystalloid solutions. Voluven (in Sweden the most commonly used colloid for replacement of bleeding during surgery) is poorly studied…
- Trial name
- NCT01195025
- Testing
- acetated Ringers, colloid, colloid+acetated Ringer
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University Hospital, Linkoeping
Cervix Carcinoma
Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix
The goal of this clinical research study is to learn if it is possible to get high-resolution microendoscopy (HRME) images of AIS tissue and/or tissue from microinvasive carcinoma right before a biopsy of the cervix.
- Trial name
- NCT02206048
- Testing
- Proflavine, High-Resolution Microendoscopy (HRME) Imaging
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- M.D. Anderson Cancer Center
Refractive Error, Myopia
Silicone Hydrogel Contact Lens Clinical and Comfort Benefits With a Multi-Purpose Disinfecting Solution
The purpose of this study was to compare lens comfort on Day 30 for Air Optix® lenses cared for with OPTI-FREE® PureMoist® (OFPM) Multi Purpose Disinfecting Solution (MPDS) compared to Acuvue® Oasys® lenses cared for with…
- Conditions
- Refractive Error, Myopia, Hyperopia, Astigmatism
- Trial name
- NCT01809197
- Testing
- Lotrafilcon B contact lenses, Senofilcon A contact lenses, OPTI-FREE PureMoist Multi-Purpose Disinfecting Solution (MPDS)
- Volunteers
- 387 people
- Sponsor
- Alcon Research
Osteoarthritis, Knee
nSTRIDE APS Versus Hyaluronic Acid for Knee Osteoarthritis
This is a two-phase multicenter, double-blind, randomized, prospective evaluation of intra-articular injection(s) comparing APS to intra-articular HA injection(s).
- Trial name
- NCT03182374
- Testing
- nSTRIDE APS, Synvisc-One
- Where
- 14 sites in Belgium, Denmark and 8 more
- Volunteers
- 252 people
- Sponsor
- Zimmer Biomet
Dry Eye Disease
A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease
SURF-100 is being studied for the treatment of dry eye disease. SURF-100 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop.
- Trial name
- NCT04734197
- Testing
- SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), Mycophenolic Acid 0.1%, Mycophenolic Acid 0.3%
- Where
- 40 sites in United States
- Volunteers
- 349 people
- Sponsor
- Surface Ophthalmics, Inc.
Healthy Volunteers
A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy Participants
The purpose of this study is to evaluate the absolute oral bioavailability (amount of drug entering the bloodstream) of spray-dried dispersion (SDD) milvexian capsules in the fed and fasted states, and to bridge the exposures…
- Trial name
- NCT04965389
- Testing
- BMS-986177 Oral Solution, [14C]BMS-986177 Solution for Infusion, BMS-986177 Spray-dried Dispersion Capsules
- Where
- United Kingdom
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Dry Eye Disease
Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
The purpose of this Phase 2a study is to assess changes in tear volume by the non-invasive techniques Ultra High Resolution Optical Coherence Tomography (UHR-OCT) following the administration of P-321 Ophthalmic Solution or…
- Trial name
- NCT02824913
- Testing
- P-321 Ophthalmic Solution
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Parion Sciences
Molluscum Contagiosum
Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.
The primary objective of the study is to determine the presence or absence of systemic cantharidin exposure from a single 24-hour dermal application of VP-102 topical film-forming solution [0.7% (w/v) cantharidin] (VP-102) when…
- Trial name
- NCT03186378
- Testing
- VP-102 with applicator
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Verrica Pharmaceuticals Inc.
Male Pattern of Hair Loss, Androgenic Alopecia
Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia
The purpose of this study is to characterize the effect of Minoxidil 5% Foam and Botanical Hair Solution Regimen in men with thinning hair and male pattern hair loss/androgenic alopecia (Norwood III \& IV).
- Trial name
- NCT02460289
- Testing
- Treatment: Minoxidil 5% / Botanical Hair Solution for Men
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Galderma R&D
Allergic Conjunctivitis
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.
The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen…
- Trial name
- NCT00770133
- Testing
- Ketotifen/naphazoline, Naphazoline, Ketotifen
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.
To evaluate the efficacy of Bilastine ophthalmic solution 0.6% compared to vehicle and Zaditen (Ketotifen ophthalmic solution 0.025%) for the treatment of the signs and symptoms of allergic conjunctivitis.
- Trial name
- NCT03479307
- Testing
- Bilastine Ophthalmic Solution 0.6%, Ketotifen Ophthalmic Solution 0.025% (Zaditen), Vehicle of Bilastine Ophthalmic Solution
- Where
- 6 sites in United States
- Volunteers
- 228 people
- Sponsor
- Faes Farma, S.A.
Acanthamoeba Keratitis
Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis
Prospective randomized study to evaluate the efficacy, safety and tolerability of 0.08% polihexanide (PHMB) eye drops in patients affected by acanthamoeba keratitis.
- Trial name
- NCT03274895
- Testing
- PHMB 0.08%, Propamidine 0.1%, PHMB 0.02%
- Where
- 6 sites in Italy, Poland and 1 more
- Volunteers
- 135 people
- Sponsor
- SIFI SpA
Acute Otitis Externa
Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Otic Solution in the Treatment of Acute Otitis Externa
This is a phase Ⅲ, multicenter, randomized, evaluator-blinded, parallel-group, active-controlled study to assess the efficacy and safety of ciprofloxacin 0.3% plus fluocinolone acetonide 0.025% otic solution vs ciprofloxacin 0.3%…
- Trial name
- NCT04636957
- Testing
- Ciprofloxacin-Fluocinolone Acetonide, 0.3%-0.025% Otic Solution, Ciprofloxacin 0.3% solution
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Lee's Pharmaceutical Limited
Common Wart
A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
The primary objective of this study is to evaluate the effectiveness of A-101 compared to Vehicle when applied to 1 Target common wart on the trunk or extremities twice a week.
- Trial name
- NCT03278028
- Testing
- A-101 Topical Solution, A-101 Vehicle Solution
- Where
- 16 sites in United States
- Volunteers
- 159 people
- Sponsor
- Aclaris Therapeutics, Inc.
Glaucoma, Primary Open Angle, Ocular Hypertension
Safety and IOP-Lowering Effects of WB007
The study evaluated the safety and IOP-lowering effects of WB007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This was a 2-part study.
- Trial name
- NCT04149899
- Testing
- WB007 0.05%, WB007 0.15%, WB007 0.4%
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Bausch & Lomb Incorporated
Ocular Hypertension, Open Angle Glaucoma
Study of AR-13324 in Patients With Elevated Intraocular Pressure
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days.
- Trial name
- NCT01528787
- Testing
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%
- Where
- 11 sites in United States
- Volunteers
- 85 people
- Sponsor
- Aerie Pharmaceuticals